Full text is available at the source.
Abstract
Type 2 diabetes (T2D) is characterized by persistent hyperglycemia and insulin resistance.
- T2D affects glucose metabolism and is marked by symptoms such as increased thirst and urination.
- The disorder is linked to dysregulated insulin secretion from pancreatic beta-cells.
- Insulin resistance in target tissues contributes to the development of T2D.
- Sulfonylureas work by stimulating specific receptors on pancreatic beta-cells to lower blood sugar.
- Other receptors, including insulin and glucagon-like peptide-1 receptors, are highlighted as potential targets for new diabetes treatments.
- Ongoing clinical research is focused on developing novel antidiabetic agents that may act through these receptors.
Simplified